“…B cell depletion via rituximab reduced synovial RANKL, expression of RANK + osteoblasts, and sera levels of bone turnover markers in patients with inflammatory OP (Wheater et al, 2011 ; Boumans et al, 2012 ). In ovariectomized and post-menopausal murine models of OP, administration of D-mannose (Liu et al, 2020 ), Bacillus calusii (Dar et al, 2018a ), and Lactobacillus acidophilus (Dar et al, 2018b ) attenuated bone loss, reduced expression of pro-inflammatory cytokines IL-6, IL-17, TNF-α, and IFN-γ, and increased expression of anti-osteoclastogenic factor IL-10 by stimulating the proliferation of Treg cells, restoring Treg/Th17 balance. Antibody-based TNF-α inhibition in a rat model of OP elevated bone density, simultaneously increased and decreased OPG and RANKL expression, respectively, and enhanced osteogenic differentiation of endogenous stromal cells (Yu et al, 2019 ).…”